FDA approved Apretude, first long-acting injectable HIV PrEP option
Dated 20 December 2021: FDA approved Apretude, first long-acting injectable HIV PrEP option. In the causal graph this event strengthens HIV/AIDS global response, a driver that strengthens Life expectancy at birth — an improving welfare path.
Who was responsible
Contribution type and responsibility level for each recorded actor — not sole-author shorthand.
No public contributors are listed for this fact.
What changed
Fact → Driver → Indicator. Relationship strength orders the paths; it is not the observed indicator movement.
- FactFDA approved Apretude, first long-acting injectable HIV PrEP option
- strengthensDriverHIV/AIDS global response
- strengthensIndicators (3)Life expectancy at birth
provisional weight · verified
Strengthens · 65% impact strength (driver → indicator)
Observed
80 Years · 2.3 below the normal line (2023)
Worse than normal6 readings, 2018–2023: rose from 79.5 Years to 80 Years.
Above normal = better
Weakens · 60% impact strength (driver → indicator)
Observed
37.4 deaths per 1,000 live births · 12.4 above the normal line (2024)
Worse than normal7 readings, 2018–2024: fell from 40 deaths per 1,000 live births to 37.4 deaths per 1,000 live births.
Above normal = worse
Strengthens · 50% impact strength (driver → indicator)
Observed
71 INDEX · 0.25 above the normal line (2023)
Better than normal6 readings, 2018–2023: rose from 69 INDEX to 71 INDEX.
Above normal = better
Causal path
How this event connects to drivers and indicators in the graph.
- FactFDA approved Apretude, first long-acting injectable HIV PrEP option
- strengthensDriverHIV/AIDS global response
- strengthensIndicatorLife expectancy at birth
Cite this page
Factrail. (2026). FDA approved Apretude, first long-acting injectable HIV PrEP option. Factrail. https://factrail.ai/facts/fda-apretude-cabotegravir-prep-2021
https://factrail.ai/facts/fda-apretude-cabotegravir-prep-2021
Accessed 16 October 2026.
By the Factrail desk · Method: how we source and score · Last reviewed
Dispute this factNamed here, or represent someone who is? Request a right of reply.